Summary
Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.
Sanjay qualified from Guy’s and St Thomas’ Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.
He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.
He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).
Publications
Journals
Eastwood M, Marc ST, Gao X, et al., 2023, Malignant Mesothelioma subtyping via sampling driven multiple instance prediction on tissue image and cell morphology data., Artif Intell Med, Vol:143
Krebs MG, Popat S, 2023, RETaliation-Tackling Rare Resistance Alterations to Osimertinib., Clin Cancer Res, Vol:29, Pages:2951-2953
Yang JC-H, Liu G, Lu S, et al., 2023, Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial., J Thorac Oncol
Hasan AMM, Cremaschi P, Wetterskog D, et al., 2023, Copy number architectures define treatment-mediated selection of lethal prostate cancer clones, Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-16
O'Sullivan H, Popat S, 2023, Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible., Lancet, Vol:402, Pages:426-427